for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nektar Therapeutics

NKTR.OQ

Latest Trade

19.90USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

13.63

 - 

28.60

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Nektar Therapeutics Posts Q2 Loss Per Share Of $0.45

Aug 6 (Reuters) - Nektar Therapeutics <NKTR.O>::REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.45.Q2 REVENUE $48.8 MILLION VERSUS $23.3 MILLION.Q2 REVENUE ESTIMATE $22.8 MILLION -- REFINITIV IBES DATA.Q2 EARNINGS PER SHARE ESTIMATE $-0.68 -- REFINITIV IBES DATA.

Nektar Therapeutics Reports First Quarter 2020 Financial Results

May 7 (Reuters) - Nektar Therapeutics <NKTR.O>::REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.78.Q1 REVENUE $50.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $47.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.77 -- REFINITIV IBES DATA.

Nektar Therapeutics Reports Q4 Loss Per Share $0.64

Feb 27 (Reuters) - Nektar Therapeutics <NKTR.O>::REPORTS FOURTH QUARTER AND YEAR-END 2019 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.64.Q4 REVENUE $33.9 MILLION VERSUS $39.8 MILLION.Q4 REVENUE ESTIMATE $26.9 MILLION -- REFINITIV IBES DATA.Q4 EARNINGS PER SHARE ESTIMATE $-0.68 -- REFINITIV IBES DATA.

Nektar Expects To Receive Additional Milestone Payment Of $25.0 Mln After Achievement Of First Patient, First Visit In Registrational Adjuvant Melanoma Trial

Jan 10 (Reuters) - Nektar Therapeutics <NKTR.O>::NEKTAR - CO TO RECEIVE ADDITIONAL MILESTONE PAYMENT OF $25.0 MILLION AFTER ACHIEVEMENT OF FIRST PATIENT, FIRST VISIT IN REGISTRATIONAL ADJUVANT MELANOMA TRIAL.NEKTAR - CO, BMS HAVE REVISED COLLABORATION THERAPIES THAT NEITHER PARTY MAY DEVELOP INDEPENDENTLY OUTSIDE COLLABORATION AGREEMENT FOR A SET PERIOD.NEKTAR - BMS SHALL HAVE RIGHT TO TERMINATE CO-FUNDING ITS SHARE OF DEVELOPMENT COSTS FOR COLLABORATION STUDY IF STUDY FAILS TO MEET PRIMARY ENDPOINT.NEKTAR THERAPEUTICS - ELIGIBLE TO RECEIVE $75 MILLION FOLLOWING ACHIEVEMENT OF 1ST PATIENT, 1ST VISIT IN REGISTRATIONAL 1ST-LINE NON-SMALL-CELL LUNG CANCER TRIAL.NEKTAR - IF BMS TERMINATES FUNDING, CO SHALL HAVE RIGHT TO CONTINUE ADJUVANT MELANOMA STUDY AS A COMBINED THERAPY INDEPENDENT STUDY.

Nektar Therapeutics And Bristol-Myers Squibb Amend Collaboration Deal For Bempegaldesleukin Plus Opdivo

Jan 10 (Reuters) - Bristol-Myers Squibb Co <BMY.N>::NEKTAR THERAPEUTICS AND BRISTOL-MYERS SQUIBB AMEND STRATEGIC COLLABORATION AGREEMENT FOR BEMPEGALDESLEUKIN PLUS OPDIVO (NIVOLUMAB).NEKTAR THERAPEUTICS - COSTS FOR STUDIES WILL BE SHARED BASED UPON COST-SHARING OUTLINED IN TERMS OF ORIGINAL COLLABORATION AGREEMENT.NEKTAR THERAPEUTICS - CO, BRISTOL AGREED TO NEW JOINT DEVELOPMENT PLAN TO ADVANCE BEMPEGALDESLEUKIN PLUS OPDIVO INTO MULTIPLE NEW REGISTRATIONAL TRIALS.NEKTAR THERAPEUTICS - BRISTOL-MYERS TO INDEPENDENTLY CONDUCT PHASE 1/2 DOSE STUDY IN FIRST-LINE NON-SMALL-CELL LUNG CANCER WITH BEMPEG AND NIVOLUMAB.NEKTAR THERAPEUTICS- PHASE 1/2 DOSE ESCALATION, EXPANSION STUDY TO BE INITIATED TO EVALUATE BEMPEG PLUS NIVOLUMAB IN COMBINATION WITH AXITINIB IN FIRST-LINE RCC.NEKTAR THERAPEUTICS - CO, BRISTOL TO EXPAND DEVELOPMENT PROGRAM FOR BEMPEG PLUS NIVOLUMAB TO INCLUDE 2 ADDITIONAL REGISTRATIONAL TRIALS.

Nektar Therapeutics Presents New Clinical And Preclinical Data From Its Immuno-Oncology Pipeline

Nov 9 (Reuters) - Nektar Therapeutics <NKTR.O>::NEKTAR THERAPEUTICS PRESENTS NEW CLINICAL AND PRECLINICAL DATA FROM ITS IMMUNO-ONCOLOGY PIPELINE AT THE 2019 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING.NEKTAR THERAPEUTICS - BEMPEG PLUS NIVO IS WELL TOLERATED, AND TREATMENT-RELATED ADVERSE EVENTS ARE PREDICTABLE AND TRANSIENT.NEKTAR-NKTR-255 IS BEING EVALUATED IN PHASE 1/2 CLINICAL TRIAL IN PATIENTS WITH EITHER RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA OR MULTIPLE MYELOMA.

Nektar Therapeutics Reports Q3 Loss Per Share Of $0.56

Nov 6 (Reuters) - Nektar Therapeutics <NKTR.O>::REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2019.Q3 LOSS PER SHARE $0.56.Q3 REVENUE $29.2 MILLION VERSUS REFINITIV IBES ESTIMATE OF $26.4 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.73 -- REFINITIV IBES DATA.

Nektar Therapeutics Q2 Loss Per Share $0.63

Aug 8 (Reuters) - Nektar Therapeutics <NKTR.O>::REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2019.Q2 LOSS PER SHARE $0.63.Q2 REVENUE $23.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $26.7 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.80 -- REFINITIV IBES DATA.CASH AND INVESTMENTS IN MARKETABLE SECURITIES AT JUNE 30, 2019 WERE $1.8 BILLION AS COMPARED TO $1.9 BILLION AT DECEMBER 31, 2018..

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo (Nivolumab)

Aug 1 (Reuters) - Nektar Therapeutics <NKTR.O>::NEKTAR THERAPEUTICS AND BRISTOL-MYERS SQUIBB ANNOUNCE U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR BEMPEGALDESLEUKIN (NKTR-214) IN COMBINATION WITH OPDIVO® (NIVOLUMAB) FOR THE TREATMENT OF PATIENTS WITH UNTREATED ADVANCED MELANOMA.

Nektar Therapeutics Receives A General Advice Letter From U.S. Food And Drug Administration

July 25 (Reuters) - Nektar Therapeutics <NKTR.O>::NEKTAR THERAPEUTICS - RECEIVED A GENERAL ADVICE LETTER FROM U.S. FOOD AND DRUG ADMINISTRATION.NEKTAR THERAPEUTICS - FDA LETTER IS REGARDING CO'S NDA FOR NKTR-181, A NOVEL MU-OPIOID ANALGESIC DRUG CANDIDATE.NEKTAR THERAPEUTICS - IN LETTER, FDA STATED THAT IT IS POSTPONING PRODUCT-SPECIFIC ADVISORY COMMITTEE MEETINGS FOR OPIOID ANALGESICS.NEKTAR THERAPEUTICS - LETTER STATED FDA'S REASON FOR POSTPONING ADVISORY COMMITTEE MEETING FOR NKTR-181 IS NOT UNIQUE TO NKTR-181 PRODUCT.NEKTAR THERAPEUTICS - LETTER FURTHER STATED THAT FDA WILL CONTINUE TO REVIEW NDA FOR NKTR-181 ACCORDING TO EXISTING PDUFA TIMELINE.NEKTAR THERAPEUTICS - FDA DID INDICATE IN LETTER THAT IT IS POSSIBLE FDA MAY NOT BE ABLE TO MEET PDUFA GOAL DATE OF AUG 29.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up